Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and FOLFIRI in Metastatic Colorectal Cancer
NCT03698253Completed
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Oct 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of regorafenib in colorectal cancer (metastatic) (mCRC), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Progression-Free Survival at 23 months. Started Oct 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03698253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698253.